Medtronic creates history with fda approval of its novel pulseselect™ pulsed field ablation system to treat atrial fibrillation

Safe, efficient, and effective treatment for both paroxysmal and persistent atrial fibrillation dublin , dec. 13, 2023 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced that the united states food and drug administration (fda) has approved the pulseselect pulsed field ablation (pfa) system for the treatment of both paroxysmal and persistent atrial fibrillation (af). this is the first pfa technology to receive fda approval and follows the recent european ce (conformitÉ europÉenne) mark of the pulseselect pfa system in november.
MDT Ratings Summary
MDT Quant Ranking